We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures
FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures
IBSA Farmaceutici did not open a corrective action, as required, for a trend in adverse events involving pain and/or swelling in the knee following injection of Sinovial or other sodium hyaluronate devices, according to a Form 483.